To guide the discussion and demonstrate the flow between translational research phases, we follow the development path of different treatments that address anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), as well as studies that demonstrate specific CTR challenges. The gene discussed is ALK; the disease is non-small cell lung carcinoma.